Please login to the form below

Not currently logged in
Email:
Password:

Genzyme’s Henk Doude van Troostwijk joins Raptor Pharmaceutical

US pharma company will also set up European headquarters in the Netherlands

Raptor Pharmaceutical has appointed Henk Doude van Troostwijk as general manager of European commercial operations.

He will be responsible for building and managing Raptor's presence in Europe following the California-based company's decision to establish European headquarters in Leiden, the Netherlands.

Doude van Troostwijk will join the company on April 15 from Sanofi's Genzyme business, where he most recently served as business unit director, oncology, for haematology and transplantation in Northern Europe.

Prior to that he held various roles at Bioenvision, MSD, Bristol-Myers Squibb and Nycomed.

At Raptor his initial focus will be on preparing for the launch and marketing of the company's RP103, an orphan treatment for cell toxicity condition nephropathic cystinosis that is currently being considered for approval by European regulatory authorities.

Patrick Reichenberger, vice president of commercial operations, said: "We are very excited to have Henk join our team to lead the commercial operations in Europe.

“His expertise in gaining market access, working with orphan products and leading commercial teams will be critical as we prepare for the potential launch of RP103 in Europe."

2nd April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics